Equillium (EQ)
(Real Time Quote from BATS)
$0.96 USD
-0.10 (-9.43%)
Updated Jun 5, 2024 11:24 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Equillium, Inc. [EQ]
Reports for Purchase
Showing records 21 - 38 ( 38 total )
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQUATE Phase 1b Trial Reports Positive Top-Line Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQUATE Data Presentation This Week; Lengthy Cash Runway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Favorable EQUALISE Phase 1b Type A Data; 2020 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Itolizumab Interim Data From EQUATE Trial Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Recent Financing Extends Operational Window; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Program on Hold; Reducing PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
FDA Clears Pivotal COVID-19 Trial to Proceed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Trial Clearance; CD6-ALCAM Insights Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Positive Initial Graft-vs.-Host Disease Data; Equity Financing; Reducing PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Putting Itolizumab in Perspective; Raising PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Itolizumab Indian Approval Holds Tantalizing Implications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
International Activity Hints at COVID-19 Role for Itolizumab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Itolizumab Progress, Albeit at Slower Pace; 1Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results; Clinical Trials Paused; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Growing Nephrology Focus; Multiple 2020 Clinical Readouts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
Business Update Provided; Additional Financing Obtained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Equillium, Inc.
Industry: Medical - Biomedical and Genetics
EQUIP Phase 1b Asthma Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R